Impact Capital Partners LLC Increases Stock Holdings in Abbott Laboratories $ABT

Impact Capital Partners LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 1.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,167 shares of the healthcare product maker’s stock after purchasing an additional 357 shares during the quarter. Abbott Laboratories accounts for 1.0% of Impact Capital Partners LLC’s investment portfolio, making the stock its 22nd biggest holding. Impact Capital Partners LLC’s holdings in Abbott Laboratories were worth $3,015,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $28,000. Elequin Capital LP purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $30,000. JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Morgan Stanley lifted their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Evercore ISI lifted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Raymond James Financial decreased their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $145.22.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $133.97 on Wednesday. The stock has a fifty day moving average price of $131.48 and a 200 day moving average price of $131.22. The stock has a market cap of $233.17 billion, a PE ratio of 16.79, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the previous year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.